Literature DB >> 21901387

The role of caveolin-1 in human breast cancer.

Neill Patani1, Lesley-Ann Martin, Jorge S Reis-Filho, Mitch Dowsett.   

Abstract

Caveolin-1 is the essential constituent protein of specialised plasma membrane invaginations called caveolae. The unique topology of caveolin-1 facilitates the role of caveolae as molecular hubs, integrating the activity of a multitude of signalling molecules. Despite improvements in our understanding of caveolin-1 interactions and the function of caveolae, the relationship between dysfunctional caveolin-1 and tumourigenesis remains contentious. Perhaps most intriguing has been the demonstration of both oncogenic and tumour suppressor function within particular tumour types, including breast cancer. In this review, the biological and clinical relevance of caveolin-1 in human breast cancer are considered. Evidence is systematically presented for the potential tumour suppressor and oncogenic functions of caveolin-1. Specific reference is made to interactions between caveolin-1 and signalling pathways in the clinical and biological subtypes of breast cancer. Areas of controversy are discussed and technical considerations are highlighted. Translational implications and potential for specific therapeutic manipulation of caveolin-1 are evaluated in the context of evidence from in vitro and in vivo studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901387     DOI: 10.1007/s10549-011-1751-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  31 in total

1.  Prometastatic NEDD9 Regulates Individual Cell Migration via Caveolin-1-Dependent Trafficking of Integrins.

Authors:  Polina Y Kozyulina; Yuriy V Loskutov; Varvara K Kozyreva; Anuradha Rajulapati; Ryan J Ice; Brandon C Jones; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2014-10-15       Impact factor: 5.852

2.  Deletion of caveolin scaffolding domain alters cancer cell migration.

Authors:  Sunaho Okada; Sadaf A Raja; Jonathan Okerblom; Aayush Boddu; Yousuke Horikawa; Supriyo Ray; Hideshi Okada; Itta Kawamura; Yoshiteru Murofushi; Fiona Murray; Hemal H Patel
Journal:  Cell Cycle       Date:  2019-05-22       Impact factor: 4.534

3.  Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

Authors:  Ayesha N Shajahan; Zachary C Dobbin; F Edward Hickman; Sivanesan Dakshanamurthy; Robert Clarke
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

4.  Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma.

Authors:  Diana Martins; Francisco F Beça; Bárbara Sousa; Fátima Baltazar; Joana Paredes; Fernando Schmitt
Journal:  Cell Cycle       Date:  2013-07-29       Impact factor: 4.534

5.  Tumor-stroma relationships: who's the driver?

Authors:  Richard F Wooster
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

6.  Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells.

Authors:  Sreeja C Sekhar; Tomonari Kasai; Ayano Satoh; Tsukasa Shigehiro; Akifumi Mizutani; Hiroshi Murakami; Bishoy Ya El-Aarag; David S Salomon; Anna Massaguer; Rafael de Llorens; Masaharu Seno
Journal:  J Cancer       Date:  2013-06-21       Impact factor: 4.207

7.  CAV1 rs7804372 (T29107A) polymorphism might be a potential risk for digestive cancers: A protocol for systematic review and meta analysis.

Authors:  Pei Chen; Yu-Ling Zhang; Bai Xue; Ji-Ru Wang
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

8.  CpG island shore methylation regulates caveolin-1 expression in breast cancer.

Authors:  X Rao; J Evans; H Chae; J Pilrose; S Kim; P Yan; R-L Huang; H-C Lai; H Lin; Y Liu; D Miller; J-K Rhee; Y-W Huang; F Gu; J W Gray; Th-M Huang; K P Nephew
Journal:  Oncogene       Date:  2012-11-05       Impact factor: 9.867

9.  PD-L1 expression is increased in a subset of basal type breast cancer cells.

Authors:  Hatem Soliman; Farah Khalil; Scott Antonia
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.

Authors:  Neill Patani; Anita K Dunbier; Helen Anderson; Zara Ghazoui; Ricardo Ribas; Elizabeth Anderson; Qiong Gao; Roger A'hern; Alan Mackay; Justin Lindemann; Robert Wellings; Jill Walker; Irene Kuter; Lesley-Ann Martin; Mitch Dowsett
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.